Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Fibrocell Science links up with Intrexon; deal expanded multiple times

Executive Summary

Fibrocell Science Inc. (cellular therapeutics) has licensed exclusive US rights to use Intrexon Corp.’s (gene-based therapies) technologies to develop next-generation genetically modified and non-genetically modified autologous fibroblasts and autologous dermal cells for all aesthetic dermal, vocal cord, and periodontal indications.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Pharmacogenetics-Pharmacogenomics
    • Drug Discovery Tools
      • Genomics-Proteomics
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Equity
    • Includes Royalty or Profit Split Information
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register